Researchers
Andrić, Zoran
Results 41-60 of 89
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2021 | A Phase 1b/2 Open-Label Study with Randomization in Phase 2 of Imu-131 Her2/Neu Peptide Vaccine Plus Standard of Care Chemotherapy in Patients with Her2/Neu Overexpressing Metastatic Or Advanced Adenocarcinoma of the Stomach Or Gastroesophageal Junction. | Maglakelidze, Marina; ...; Andric, Zoran G   ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zoran; ...; (broj, koautora 17) | Conference Paper | Mp. category will be shown later |
| 2021 | Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC | Jassem, Jacek; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Article | 21a+M21a+ |
| 2021 | First-line avelumab in combination with cetuximab and chemotherapy in patients with advanced squamous non-small cell lung cancer (NSCLC) | Andric, Zoran G ; ...; Stojanovic, Goran; Petrovic, Marina D ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2021 | Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC) | Syrigos, Konstantinos; Abert, Istvan; Andric, Zoran G ; Bondarenko, Igor N; Dvorkin, Mikhail; Galic, Kristina; Galiulin, Rinat; Kuchava, Vladimer; Sriuranpong, Virote; Trukhin, Dmytro;
Zhavrid, Edvard; Fu, Dongyue; Kassalow, Laurent M; Jones, Stephanie; Bashir, Zahid;
| Article | 21aM21a |
| 2021 | HERIZON: Phase 2 part of the IMU-131 HER2/neu vaccine plus chemotherapy study randomized in patients with HER2/NEU overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction | Maglakelidze, Marina; ...; Andric, Zoran G ; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z ; Petrovic, Zeljko M; ...; (broj, koautora 16) | Conference Paper | Mp. category will be shown later |
| 2021 | A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression | Andric, Zoran G ; Ceric, Timur; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Ulanska, M; Caldwell, C; Ferrari, D; Annis, A;
Vukovic, V; Zaric, Bojan
; | Conference Paper | Mp. category will be shown later |
| 2021 | Polycystic Ovary Syndrome: A Contemporary Clinical Approach | Bjekić-Macut, Jelica ; Vukašin, Tamara; Velija-Ašimi, Zelija; Bureković, Azra; Zdravković, Marija ; Andrić, Zoran ; Branković, Marija ; Crevar-Marinović, Slobodanka; Mandić, Tatjana; Stanojlović, Olivera ;
Vojnović-Milutinović, Danijela
; Livadas, Sarantis; Mastorakos, George; | Article | 22M22 |
| 2021 | HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal j | Laeufle, Rita; ...; Andric, Zoran G ; ...; Nikolic, Ivan V ; ...; Radosavljevic, Davorin Z; ...; (broj, koautora 16) | Conference Paper | Mp. category will be shown later |
| 2021 | Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA) | Trukhin, Dmytro; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Article | 21aM21a |
| 2020 | Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 22) | Article | 21a+M21a+ |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Conference Paper | Mp. category will be shown later |
| 2020 | Prevention of Chemotherapy-induced Myelosuppression in SCLC patients treated with the Dual MDMX/MDM2 Inhibitor ALRN-6924 | Andric, Zoran G ; Ceric, Timur; Stanetic, Mirko; Rancic, Milan H ; Jakopovic, Marko; Aix, S Ponce; Ramlau, Rodryg; Smit, E; Ulanska, M; Caldwell, C;
Ferrari, D; Annis, A; Vukovic, V; Zaric, Bojan
; | Conference Paper | Mp. category will be shown later |
| 2020 | Myelopreservation and reduced use of supportive care with trilaciclib in patients with small cell lung cancer. | Jared, Weiss; Jerome, Goldschmidt; Andric, Zoran G ; Konstantin, Dragnev H; Yili, Pritchett; Shannon, Morris R; Rajesh, Malik K; Davey, Daniel B | Conference Paper | Mp. category will be shown later |
| 2020 | Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC | Reinmuth, Niels; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2020 | Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, PlaceboControlled Phase II Study | Hart Lowel L; Ferrarotto Renata; Andrić Zoran G ; Beck Thaddeus J; Subramanian Janakiraman; Radosavljević Davorin Z ; Zarić Bojan ; Hanna Wahid T; Aljumaily Raid; Owonikoko Taofeek K;
Verhoeven Didier; Xiao Jie; Morris Shannon R; Antal Joyce M; Hussein Maen A;
| Article | 21M21 |
| 2020 | Hypertension in Polycystic Ovary Syndrome: Novel Insights | Macut, Đuro ; Mladenović, Violeta ; Bjekić-Macut, Jelica ; Livadas, Sarantis; Stanojlović, Olivera ; Hrnčić, Dragan ; Rašić-Marković, Aleksandra ; Vojnović-Milutinović, Danijela ; Andrić, Zoran | Article | 23M23 |
| 2020 | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial | Mansfield, AS; ...; Andric, Zoran G ; ...; (broj, koautora 19) | Article | 21a+M21a+ |
| 2020 | Bevacizumab biosimilar and reference bevacizumab in subjects with stage IIIB/IV no squamous non-small cell lung cancer (NSCLC) (STELLA study): Results for the primary endpoint in a confirmatory, double-blind, randomized, controlled study. | Millan, Susana; Trukhin, Dmytro; Kolesnik, Oleksii; Poddubskaya, Elena; Andric, Zoran G ; Bondarenko, Igor N; Shevnia, Serhii; Bullo, Felicitas; Sarnago, Cristina | Conference Paper | Mp. category will be shown later |
| 2020 | Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2019 | IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC | Spigel, D; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |